Core Viewpoint - AtaiBeckley Inc. is hosting a Virtual Investor Day on March 6, 2026, to present its mission and pipeline of mental health treatments [1][2]. Company Overview - AtaiBeckley Inc. is a clinical-stage biotechnology company focused on developing rapid-acting, durable, and convenient mental health treatments [3]. - The company's pipeline includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder [3]. - BPL-003 is in Phase 3 planning, while VLS-01 and EMP-01 are in Phase 2 clinical development [3]. - The company is also working on a drug discovery program for novel, non-hallucinogenic 5-HT2AR agonists targeting opioid use disorder and TRD [3]. Event Details - The Virtual Investor Day will feature presentations and live Q&A sessions with the executive leadership team and external key opinion leaders [1]. - Investors, analysts, and media members can register for the live webcast, with a replay available afterward on the company's investor website [2].

Core Insights - AtaiBeckley Inc. is focused on developing innovative mental health treatments aimed at improving patient outcomes [1][3] - The company will participate in several investor conferences in March, including fireside chats and one-on-one meetings [1][2] Company Overview - AtaiBeckley is a clinical-stage biotechnology company dedicated to creating rapid-acting, durable, and convenient mental health treatments [3] - The company's pipeline includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD, and EMP-01 ((R)-MDMA HCI) for social anxiety disorder [3] - BPL-003 is currently in Phase 3 planning, while VLS-01 and EMP-01 are in Phase 2 clinical development [3] - AtaiBeckley is also working on a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for opioid use disorder and TRD [3] Upcoming Events - The company will host a fireside chat on March 4 from 11:50 am to 12:20 pm EST in Boston, Massachusetts [5] - One-on-one meetings are scheduled for March 10 in Miami, Florida [5] - Another fireside chat will take place on March 11 from 8:00 am to 8:30 am EST, also in Miami [5]

Core Insights - AtaiBeckley Inc. is a clinical-stage biotechnology company focused on developing rapid-acting and durable mental health treatments, recently participating in the 64th Annual Meeting of the American College of Neuropsychopharmacology (ACNP) [1][6] Group 1: Clinical Data Presentation - Dr. David Feifel presented data from AtaiBeckley's Phase 2b study of BPL-003, showing that a single 8 mg or 12 mg dose resulted in significant, rapid, and sustained antidepressant effects in treatment-resistant depression (TRD) compared to a 0.3 mg control dose, with both active doses well-tolerated [2] - The findings from the Phase 2b study highlight the potential benefits of BPL-003 in treating TRD and indicate the need for further investigation in Phase 3 trials [2] Group 2: Preclinical Research - Dr. Michelle Kokkinou presented a preclinical study on 5-MeO-DMT, indicating its pharmacological and pharmacokinetic profile, which supports its therapeutic use for mood disorders and suggests potential mechanisms related to neuroplasticity [3] Group 3: Company Statements and Future Directions - Dr. Kevin Craig, Chief Medical Officer, expressed satisfaction with the recognition of BPL-003's results as a Hot Topic at ACNP, emphasizing the strength of the clinical findings in TRD and the commitment to breakthroughs in mental health [4] - AtaiBeckley's pipeline includes BPL-003 for TRD, VLS-01 for TRD, and EMP-01 for social anxiety disorder, all in Phase 2 clinical development, along with a drug discovery program for non-hallucinogenic 5-HT2AR agonists [6]

Core Argument - The mental health field should move beyond diagnosis and consider the individual's context, history, and societal influences [6][11][18] - Mental health diagnoses are valuable tools but should not overshadow the individual's unique experiences and the broader societal factors contributing to their distress [7][8] - Systemic oppression, societal expectations, and cultural realities significantly impact mental health, particularly for marginalized communities [5][12][13] Societal Impact on Mental Health - Societal structures and policies, such as discrimination and lack of inclusive education, contribute to mental health challenges [3][12][13] - The mental health field needs to understand the intersection of societal structures and individual experiences to provide effective treatment [14] - Stigma associated with mental health labels can perpetuate misunderstanding and reduce individuals to a set of symptoms [10] Holistic Approach to Mental Health - Mental health professionals, educators, families, and society should see the whole person, considering their context, culture, and history [11][18] - A compassionate and effective approach to mental health involves honoring the fullness of an individual's experience and recognizing their strengths [16][17] - Encourages a shift from asking "what is wrong with you" to "what happened to you" to understand the individual's pain and help them reclaim their strengths [19] Resilience and Empowerment - Despite challenges, individuals and communities demonstrate resilience in the face of adversity [14][15] - Empowering individuals by exploring their identity, community, and history can help them overcome mental health challenges [15][16] - Recognizing and honoring the strengths of individuals, such as creativity and meticulousness, can be an effective approach to mental health care [17]

Group 1 - Company atai Life Sciences is a clinical-stage biopharmaceutical firm focused on developing effective mental health treatments to improve patient outcomes [1][3] - The company has a pipeline of psychedelic-based therapies, including BPL-003 for treatment-resistant depression (TRD), VLS-01 for TRD, and EMP-01 for social anxiety disorder, all currently in Phase 2 clinical development [3] - atai is also working on a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD, aiming to provide scalable interventional psychiatry therapies [3] Group 2 - atai Life Sciences will participate in several investor conferences in September, including the Cantor Global Healthcare Conference on September 5, H.C. Wainwright Annual Global Investment Conference on September 8, and TD Cowen Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit on September 17 [1][2] - The format for these conferences will be fireside chats, and webcasts will be available on the company's website [2]

Core Insights - BrainsWay has made a strategic investment of $5 million in Neurolief, which is developing the Proliv™Rx device pending FDA approval for treating Major Depressive Disorder (MDD) outside of clinical settings [1][2][4] - Neurolief's technology aims to address the significant gap in accessible therapies for treatment-resistant MDD patients, who often face prolonged suffering and higher healthcare costs [3][4] - The partnership is expected to enhance both companies' market presence and expand access to innovative mental health treatments [2][4] Company Overview - BrainsWay is a leader in non-invasive neurostimulation treatments for mental health disorders, with its Deep TMS™ platform technology having three FDA-cleared indications [6][7] - Neurolief is a pioneering company focused on developing wearable, non-invasive neuromodulation systems for mental health and neurological disorders, with its Relivion®MG therapy already approved for migraine treatment [8] Financial Aspects - The investment agreement includes potential milestone-based funding, with a second tranche of up to $6 million contingent on FDA approval of Neurolief's Proliv™Rx system, and a third tranche of up to $5 million based on revenue milestones [4] - The strategic investment is seen as a validation of Neurolief's technology and vision, aiming to reshape the treatment landscape for depression [4]